METHOD FOR PREDICTING DURATION OF DISEASE-FREE INTERVAL AFTER COMPLETION OF PRIMARY TREATMENT OF PATIENTS WITH OVARY CANCER Russian patent published in 2019 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to methods for interpreting laboratory test results. From the totality of the results of assessing the levels of tumor-associated markers, the duration of the disease-free interval is predicted, and in case: in patients younger than 40 years, the concentration of CA125 is higher than 35 units/ml and/or the concentration of HE4 is higher than 70 pmol/l; in patients aged 40–50, the concentration of CA125 is higher than 35 units/ml and/or the concentration of HE4 is higher than 100 pmol/l; in patients older than 50 years, the concentration of CA125 is higher than 35 units/ml and/or the concentration of HE4 is higher than 120 pmol/l, while the relapse-free course after the end of the primary treatment will not exceed one year.

EFFECT: invention can be used in ovarian cancer to improve the results of treatment by increasing the number of courses or modifying the tactics of adjuvant chemotherapy with unfavorable values of markers.

1 cl, 4 ex, 1 tbl